EnteroMedics (RSLS) Sets New 12-Month High and Low at $0.61

EnteroMedics (NASDAQ:RSLS) hit a new 52-week high and low during trading on Wednesday . The company traded as low as $0.61 and last traded at $0.65, with a volume of 229183 shares changing hands. The stock had previously closed at $0.65.

RSLS has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of EnteroMedics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 17th. ValuEngine raised shares of EnteroMedics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st.

How to Become a New Pot Stock Millionaire

The stock has a market cap of $20.35, a P/E ratio of -0.21 and a beta of 2.52.

An institutional investor recently bought a new position in EnteroMedics stock. Anson Funds Management LP bought a new stake in EnteroMedics (NASDAQ:RSLS) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 219,016 shares of the medical device company’s stock, valued at approximately $324,000. Anson Funds Management LP owned approximately 0.73% of EnteroMedics at the end of the most recent quarter. Institutional investors own 20.16% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “EnteroMedics (RSLS) Sets New 12-Month High and Low at $0.61” was originally published by Week Herald and is owned by of Week Herald. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://weekherald.com/2018/04/18/enteromedics-rsls-sets-new-12-month-high-and-low-at-0-61.html.

EnteroMedics Company Profile

ReShape Lifesciences Inc, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses.

Receive News & Ratings for EnteroMedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply